Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis

Abdel-Maged, Amany El-Shahawy; Gad, Amany M.; Abdel-Aziz, Amal Kamal; Aboulwafa, Mohammad M.; Azab, Samar S.

doi:10.1016/j.taap.2018.07.014

Cited by 24 publications

(11 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects on inflammatory, angiogenesis, apoptosis inhibition were observed in both groups. Interestingly, anti-VEGF reduces the bone and cartilage destruction compared to methotrexate or tocilizumab treatment [74]. Another anti-VEGF signaling agent, Ramucirumab, is a monoclonal antibody against the VEGFR2, and co-therapy with methotrexate showed synergistic effects in a RA experimental model.…”

Section: Vegf In Ramentioning

confidence: 99%

Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases

Kwon

2021

IJMS

View full text Add to dashboard Cite

Rheumatic diseases constitute a diversified group of diseases distinguished by arthritis and often involve other organs. The affected individual has low quality of life, productivity even life-threatening in some severe conditions. Moreover, they impose significant economic and social burdens. In recent years, the patient outcome has been improved significantly due to clearer comprehension of the pathology of rheumatic diseases and the effectiveness of “treat to target” therapies. However, the high cost and the adverse effects are the concerns and full remissions are not often observed. One of the main processes that contributes to the pathogenesis of rheumatic diseases is angiogenesis. Vascular endothelial growth factor (VEGF), a central mediator that regulates angiogenesis, has different isoforms and functions in various physiological processes. Increasing evidence suggests an association between the VEGF system and rheumatic diseases. Anti-VEGF and VEGF receptor (VEGFR) therapies have been used to treat several cancers and eye diseases. This review summarizes the current understanding of VEGF biology and its role in the context of rheumatic diseases, the contribution of VEGF bioavailability in the pathogenesis of rheumatic diseases, and the potential implications of therapeutic approaches targeting VEGF for these diseases.

show abstract

Section: Vegf In Ramentioning

confidence: 99%

Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases

Kwon

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…We selected adjuvant-induced arthritis (AIA) because it mimics the signs and symptoms of human RA, such as the histopathological changes of inflammation, vascular proliferation, and importantly, the progression to joint destruction [18]. The AIA model has been widely used in the development of antirheumatic drugs, including several non-steroid anti-inflammatories, methotrexate [19], and also biologic drugs, including tocilizumab [20] and Jak-inhibitors like tofacitinib [21].…”

Section: Introductionmentioning

confidence: 99%

Exercise Exacerbates the Transcriptional Profile of Hypoxia, Oxidative Stress and Inflammation in Rats with Adjuvant-Induced Arthritis

González-Chávez

Quiñonez-Flores

Espino-Solís

et al. 2019

Cells

View full text Add to dashboard Cite

Physical exercise (PE) is recommended for Rheumatoid Arthritis (RA), but the molecular and biological mechanisms that impact the inflammatory process and joint destruction in RA remain unknown. The objective of this study was to evaluate the effect of PE on the histological and transcriptional changes in the joints of adjuvant-induced arthritis (AIA) rat model. AIA rats were subjected to PE on a treadmill for eight weeks. The joints were subjected to histological and microarray analysis. The differentially expressed genes (DEGs) by PE in the arthritic rats were obtained from the microarray. The bioinformatic analysis allowed the association of these genes in biological processes and signaling pathways. PE induced the differential expression of 719 genes. The DEGs were significantly associated with pathogenic mechanisms in RA, including HIF-1, VEGF, PI3-Akt, and Jak-STAT signaling pathways, as well as response to oxidative stress and inflammatory response. At a histological level, PE exacerbated joint inflammatory infiltrate and tissue destruction. The PE exacerbated the stressed joint environment aggravating the inflammatory process, the hypoxia, and the oxidative stress, conditions described as detrimental in the RA joints. Research on the effect of PE on the pathogenesis process of RA is still necessary for animal models and human.

show abstract

“…COX-2 (PTGS2) is the rate-limiting enzyme of arachidonic acid metabolism, which controls the production of PGE 2 , the proin ammatory mediators of autoimmunity activities [25][26][27] . VEGF is an essential angiogenic marker for RA disorders [28][29][30] . TP53 and CASP3 regulate the apoptosis of rheumatoid synovial cells [31][32] .…”

Section: Network Pharmacology Unraveled Crucial Anti-ra Targets Of Geramentioning

confidence: 99%

The Anti-RA Activities of a Couplet Medicinals, Gastrodia Elata and Radix Aconitic Lateralis preparata, Explored by Untargeted Metabolomics and Network Pharmacology.

Yang¹,

Shen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The couplet Medicinals, Gastrodia Elata and Radix Aconitic Lateralis preparata (GERA), is an established formula extensively used in Chinese medicine for treating rheumatoid arthritis (RA). However, the anti-RA mechanisms of GERA are still unclear. This paper aims to explore the anti-RA mechanisms of GERA by a combined strategy of untargeted metabolomics and network pharmacology. Methods Three water extracts were prepared as propotions: Gastrodia Elata compared with Radix Aconitic Lateralis (w/w): 1:1, 3:2, or 2:3. The untargeted metabolomics were executed with UPLC-MS. The metabolites were annotated and identified by Human metabolome database (HMDB) and Lipid maps database. Finally, key genes and pathways related to anti-RA activities of GERA were mined by network pharmacology. Results The untargeted metabolomics profile displayed that four differentially expressed metabolites were involved in isoflavonoid biosynthesis and biosynthesis of unsaturated fatty acids (p < 0.05). Among these differential metabolites, the essential ingredients of GERA were linoleic acid, daidzein, and daidzin. The principal targets of anti-RA activities of GERA were IL-6, TNF, VEGFA, TP53, CASP3 and PTGS2. Thirty anti-RA targets of GERA were majorly belonged to pathways response for anti-inflammation, endothelial function and apoptosis, suggesting the fundamental process of RA treatment. Conclusion The anti-RA activities of GERA were based on the inhibition of inflammation and regulation of endothelial function and apoptosis.

show abstract

Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis

Cited by 24 publications

References 52 publications

Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases

Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases

Exercise Exacerbates the Transcriptional Profile of Hypoxia, Oxidative Stress and Inflammation in Rats with Adjuvant-Induced Arthritis

The Anti-RA Activities of a Couplet Medicinals, Gastrodia Elata and Radix Aconitic Lateralis preparata, Explored by Untargeted Metabolomics and Network Pharmacology.

Contact Info

Product

Resources

About